Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2007-06-19
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S255030, C514S256000, C514S327000, C514S424000, C514S563000, C514S568000, C548S543000, C560S059000, C562S469000, C562S432000, C562S452000, C546S322000, C546S326000, C546S301000, C544S172000, C544S224000, C544S406000, C544S407000
Reexamination Certificate
active
10508761
ABSTRACT:
Compounds of formula (I) or a pharmaceutically acceptable derivative thereof:wherein A, R1, R2, Rx, R8, R9and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
REFERENCES:
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5420287 (1995-05-01), Reitz et al.
patent: 5424450 (1995-06-01), Boswell et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5512681 (1996-04-01), Boswell et al.
patent: 5663180 (1997-09-01), Reitz et al.
patent: 5811459 (1998-09-01), Oldfield et al.
patent: 5840746 (1998-11-01), Ducharme et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6440963 (2002-08-01), Leonardi et al.
patent: 6495149 (2002-12-01), Scavone et al.
patent: 2002/0045605 (2002-04-01), Kargman et al.
patent: 4032522 (1992-04-01), None
patent: 4034728 (1992-05-01), None
patent: 20211496 (2002-11-01), None
patent: 131302 (1985-01-01), None
patent: 540009 (1993-05-01), None
patent: 03/03661 (1993-09-01), None
patent: 1251126 (2002-10-01), None
patent: 1264847 (2002-12-01), None
patent: 2272899 (1994-06-01), None
patent: 04076087 (1992-03-01), None
patent: 04235933 (1992-08-01), None
patent: 05224442 (1993-09-01), None
patent: 06065213 (1994-03-01), None
patent: 2002363748 (2002-12-01), None
patent: WO 93/04045 (1993-03-01), None
patent: WO 93/04046 (1993-03-01), None
patent: WO 94/05658 (1994-03-01), None
patent: WO 95/00501 (1995-01-01), None
patent: WO 95/05372 (1995-02-01), None
patent: WO 95/11883 (1995-05-01), None
patent: WO 95/17393 (1995-06-01), None
patent: WO 96/11676 (1996-04-01), None
patent: WO 96/36623 (1996-11-01), None
patent: WO 96/37496 (1996-11-01), None
patent: WO 96/41645 (1996-12-01), None
patent: WO 97/03667 (1997-02-01), None
patent: WO 97/11701 (1997-04-01), None
patent: WO 97/16435 (1997-05-01), None
patent: WO 97/38986 (1997-10-01), None
patent: WO 98/16227 (1998-04-01), None
patent: WO 98/25896 (1998-06-01), None
patent: WO 98/55468 (1998-12-01), None
patent: WO 99/17776 (1999-04-01), None
patent: WO 99/58487 (1999-11-01), None
patent: WO 00/47553 (2000-08-01), None
patent: WO 00/53149 (2000-09-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 01/19814 (2001-03-01), None
patent: WO 01/081332 (2001-11-01), None
patent: WO 02/099435 (2002-12-01), None
Stock et. al., “The Prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure”, J. Clin. Invest. 17: 325-331.
Whitesell, J.K., et al. “Synthesis and Resolution of a New Chiral C2-Symmetric Bisphenol: Trans-1,2-Bis(2-Hydroxyphenyl)cyclopentane.” Tetrahedron Letters, 1997, 38(15), pp. 2589-2592.
Rathore, R., et al. “Efficient Hydrogenation of Sterically Hindered Olefins with Borane-Methyl Sulfide Complex.” Journal of Organic Chemistry, 1996, 61(16), pp. 5246-5256.
Malik, O.P., et al. “Studies on Cannabinoids: Part III. Synthesis of 9,10,11,11a-Tetrahydro-6H,8H-Pyrido(1,2-c [1,3]benzoxazine.” Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1976, 14B(12), pp. 975-978.
Ahmad, et al.; Prostaglandin EP1 Receptor Contributes to Excitotoxicity and Focal Ischemic Brain Damage; Toxicological Sciences; Oct. 19, 2005; 69(1): 265-270; Oxford University Press.
Kawahara, et al.; A Prostaglandin E2 Receptor Subtype EP1 Receptor Antagonist (ONO-8711) Reduces Hyperalgesia, Allodynia, and C-fos Gene Expression in Rats with Chronic Nerve Constriction; Aneslh Analg; 2001: 93: 1012-7; International Anesthesia Research Society.
Kawano, et al.; Prostaglandin E2 EP1 Receptors: Downstream Effectors of Cox-2 Neurotoxicity; Nature Medicine; Feb. 2006; 12(2); 225-229; Nature Publishing Group.
Omote, et al.; The Effects of Intrathecal Administration of an Antagonist for Prostaglandin E Receptor Subtype EP1 on Mechanical and Thermal Hyperalgesia in a Rat Model of Postoperative Pain; Anesth Analg; 2002; 95; 1708-12; International Anesthesia Research Society.
Omote, et al.; The Effects of Peripheral Administration of a Novel Selective Antagonist for Prostaglandin E Receptor Subtype EP1, ONO-8711, in a Rat Model of Postoperative Pain; Anesth Analg; 2001; 92; 233-6; International Anesthesia Research Society.
Stock, et al.; The Prostaglandin E2 EP1 Receptor Mediates Pain Perception and Regulates Blood Pressure; The Journal of Clinical Investigation: Feb. 2001; 107(3); 325-331.
Giblin Gerard Martin Paul
Hall Adrian
Hurst David Nigel
Kilford Ian Reginald
Lewell Xiao Qing
Dentz Bernard
Glaxo Group Limited
Robinson Binta
Young J. Scott
LandOfFree
(2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3855949